Patients for Affordable Drugs (P4AD) in a new report targeting GlaxoSmithKline (GSK) claims the drugmaker has displayed a “pattern of … abusing the system in order to maintain monopolies on their products and keep prices high for patients.”
The organization in its report claims the drugmaker has, since the early 2000s, “exploited loopholes” in the 1984 Hatch-Waxman Act to prevent more affordable generic versions of their drugs from entering the marketplace.
“By filing frivolous patent infringement lawsuits to trigger an automatic pause on FDA approval of generics, GSK delayed the entry of a generic version of Paxil by 65 months,” the report alleges, citing a study by the Federal Trade Commission.
To read the full report, click here.
